Mineralys Shares Fall After FDA Accepts NDA for Lorundrostat – Explore-OSA Misses Primary Endpoint but Delivers Strong BP Reduction
Mineralys receives FDA acceptance of NDA for lorundrostat for hypertension. PDUFA target date: December 22, 2026. Explore-OSA missed primary endpoint but demonstrated meaningful BP reduction.
